Answers are grounded in this paper and cite their sources.
Background Pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint blockade (ICB), partly because of an immunosuppressive tumor microenvironment. PAPSS1 is a metabolic enzyme that can localize to the nucleus, but its contribution to PDAC progression and immune suppression remains unclear. Methods We conducted an in vivo CRISPR-Cas9 metabolic screen in mouse PDAC models. Widely-targeted metabolomics, co-immunoprecipitation, chromatin immunoprecipitation, and immunofluorescence were used to dissect the underlying mechanism. Syngeneic subcutaneous, orthotopic, and liver metastasis models were established. Tumor-infiltrating immune cells were analyzed by flow cytometry and multiplex immunofluorescence. Clinical PDAC specimens were evaluated by immunohistochemistry and quantitative PCR. Results Nuclear PAPSS1 enrichment was associated with poor survival in patients with PDAC. Mechanistically, catalytically active nuclear PAPSS1 promoted intracellular accumulation of p-tolyl sulfate (PTS). PTS enhanced CBX3–EP300 association and increased H3K4 acetylation at the promoters of SLC16A3 (MCT4) and CXCL3 . These changes engaged two complementary immunosuppressive pathways: SLC16A3-mediated lactate efflux contributed to CD8⁺ T-cell exhaustion, whereas CXCL3 promoted CXCR2-dependent neutrophil recruitment. Combined restoration of SLC16A3 and CXCL3 in PAPSS1-silenced tumor cells restored tumor growth and immunosuppressive features in vivo. Combining anti-PD-1 therapy with MCT1/MCT4 inhibition and CXCR2 antagonism reduced the proportions of PD-1⁺TIM-3⁺ CD8⁺ T cells and neutrophils, suppressed tumor growth, and prolonged survival in mice. Conclusions Nuclear PAPSS1 enrichment is associated with poor prognosis in patients with PDAC. The PAPSS1–PTS–CBX3–EP300–H3K4ac axis links sulfate metabolism to immune evasion through SLC16A3 and CXCL3 regulation. Combined inhibition of lactate transport and CXCR2 enhances the antitumor activity of anti-PD-1 therapy in mouse models, providing a preclinical rationale for this combination strategy. Statement of significance Nuclear PAPSS1 promotes PTS accumulation and CBX3–EP300 association, linking sulfate metabolism to immune evasion and supporting combined targeting of lactate transport and CXCR2 alongside anti-PD-1 therapy in mouse models.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: